Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study (vol 1, pg 27, 2011)

被引：0
|
作者：
Morgan, C. Ll
机构：
来源：
CLINICAL THERAPEUTICS | 2011年 / 33卷 / 03期
关键词：
D O I：
10.1016/j.clinthera.2011.03.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：391 / 391
页数：1
相关论文
共 50 条
  • [31] Evaluating the cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for the treatment of type 2 diabetes in a Spanish setting
    Tucker, D.
    Valentine, W. J.
    Nielsen, S.
    Townsend, C.
    Kotchie, R.
    Scheijbeler, H.
    VALUE IN HEALTH, 2007, 10 (06) : A263 - A263
  • [32] Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: Results from the ASEAN subgroup of the A1chieve study
    Hussein, Zanariah
    Lim-Abrahan, Mary Anne
    Jain, Anand B.
    Goh, Su Yen
    Soewondo, Pradana
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 100 : S24 - S29
  • [33] Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study
    Chen, JW
    Lauritzen, T
    Christiansen, JJ
    Jensen, LH
    Clausen, WHO
    Christiansen, JS
    DIABETIC MEDICINE, 2005, 22 (03) : 273 - 277
  • [34] Biphasic Insulin Aspart 30/70 (BIAsp 30) Is Well Tolerated Effective in Patients ≥75 Years Old in the IMPROVE™ Study
    Borzi, Vito
    Rosenberg, Kristine Horn
    Benroubi, Marian
    DIABETES, 2010, 59 : A554 - A555
  • [35] Comment on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients:: cost-effectiveness analysis in the UK setting -: Reply
    Valentine, William J.
    Palmer, Andrew J.
    Lammert, Morten
    Nicklasson, Lars
    Foos, Volker
    Roze, Stephane
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 968 - 969
  • [36] Ten Years of Experience with Biphasic Insulin Aspart 30 From Drug Development to the Latest Clinical Findings
    Liebl, Andreas
    Prusty, Vinay
    Valensi, Paul
    Kawamori, Ryuzo
    Christiansen, Jens Sandahl
    Palmer, Andrew J.
    Balschmidt, Per
    Ligthelm, Robert
    Mohan, Viswanathan
    DRUGS, 2012, 72 (11) : 1495 - 1520
  • [37] Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study
    Shestakova, M.
    Sharma, S. K.
    Almustafa, M.
    Min, K. W.
    Ayad, N.
    Azar, S. T.
    Danciulescu, R.
    Khutsoane, D.
    Guler, S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3209 - 3214
  • [38] Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
    Valensi, P.
    Benroubi, M.
    Borzi, V.
    Gumprecht, J.
    Kawamori, R.
    Shaban, J.
    Shah, S.
    Shestakova, M.
    Wenying, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 522 - 531
  • [39] LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS
    Ligthelm, R.
    Christensen, T. E.
    Thomsen, T. L.
    Yang, W.
    VALUE IN HEALTH, 2009, 12 (07) : A402 - A402
  • [40] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
12345